The Quantellect read.As of Nov 19, 2026, 8 active firms cover 4D Molecular Therapeutics Inc: 8 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $20.00 to $37.00, a moderate spread. The average target of $30.00 sits 187% above the current $10.47. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.13 next quarter toward $-4.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy8100%
Neutral00%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$30.00
+186.5% upside
Average target across 8 active firms as of Nov 19, 2026 vs $10.47 current
Highest Target$37.00
Average Target$30.00
Lowest Target$20.00
Detailed analyst forecasts for FDMT
Showing 1–9 of 9 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 8 of 8 active firms rate FDMT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
FDMT EPS & revenue forecast
EPS · NEXT QUARTER
$-1.13
Range $-1.19 – $-1.06 · 2 analysts · +11% YoY
Next period, 2 analysts expect 4D Molecular Therapeutics Inc to earn $-1.13 a share (range $-1.19 – $-1.06), versus $-1.01 a year earlier. Full-year consensus is $-4.16, growing to $-4.19 the year after.
REVENUE · NEXT QUARTER
$2.5M
Range $0 – $5.0M · 2 analysts · -18% YoY
Revenue is expected to reach $2.5M (range $0 – $5.0M), -18.0% year-over-year. Full-year consensus is $13.1M, rising to $16.8M next year.
Top analysts covering 4D Molecular Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FDMT.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$37.00+253.4% to target
Overall win rate
49%
+ Follow
#2
Luca Issi
RBC Capital · Rank #76
Buy
$35.00+234.3% to target
Overall win rate
49%
+ Follow
#3
Geulah Livshits
Chardan Capital · Rank #104
Buy
$26.00+148.3% to target
Overall win rate
43%
+ Follow
#4
Josh Schimmer
Cantor Fitzgerald · Rank #132
Buy
$20.00+91.0% to target
Overall win rate
44%
+ Follow
#5
MC
Matthew Caufield
HC Wainwright & Co. · Rank #155
Buy
$36.00+243.8% to target
Overall win rate
49%
+ Follow
FDMT stock forecast FAQ
What is FDMT's average 12-month price target?+
The 8 active firms with a live target average $30.00 for 4D Molecular Therapeutics Inc over the next 12 months, ranging from a $37.00 high to a $20.00 low, as of Nov 19, 2026.
Is FDMT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for FDMT?+
The Street-high target is $37.00 (B. Riley Securities), and the Street-low is $20.00 (Cantor Fitzgerald). The average of all 8 active-firm targets is $30.00.
How many active Wall Street firms cover FDMT?+
8 active firms have a recognized rating on 4D Molecular Therapeutics Inc as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering FDMT?+
Among analysts who currently cover FDMT, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $37.00 target.
What is 4D Molecular Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.13 per share (range $-1.19 – $-1.06) across 2 analysts. Full-year EPS is projected at $-4.16, rising to $-4.19 the following year.
How much revenue is 4D Molecular Therapeutics Inc expected to report next quarter?+
Consensus revenue is $2.5M (range $0 – $5.0M). Full-year revenue is projected at $13.1M, growing to $16.8M next year.
Have analysts been upgrading or downgrading FDMT lately?+
As of Nov 19, 2026, 8 of 8 active firms rate FDMT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FDMT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.